| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | その他(不明) |
| 表題 | Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an international multicentre study. |
| 掲載誌名 | 正式名：British journal of cancer 略 称：Br J Cancer ISSNコード：15321827/00070920 |
| 掲載区分 | 国外 |
| 巻・号・頁 | pp.Online ahead of print |
| 著者・共著者 | Thomas F Stoop, Y H Andrew Wu, Atsushi Oba, Mahsoem Ali, Isabel M Feld, Mohammed H Al-Musawi, Ajay Jain, Akio Saiura, Alain Sauvanet, Alessandro Coppola, Ammar A Javed, Bas Groot Koerkamp, Braden N Miller, Daisuke Hashimoto, Damiano Caputo, Dyre Kleive, Elisabetta Sereni, Geert Kazemier, Giulio Belfiori, Hirofumi Ishida, Jacob L van Dam, Jeanne Dembinski, Keiichi Akahoshi, Keith J Roberts, Kimitaka Tanaka, Knut J Labori, Massimo Falconi, Michael G House, Motokazu Sugimoto, Minoru Tanabe, Naoto Gotohda, Nikolaos Chatzizacharias, Paul S Krohn, Safi Dokmak, Salvador Rodriguez Franco, Satoshi Hirano, Stefan K Burgdorf, Stefano Crippa, Sohei Satoi, Trang K Nguyen, Tomohisa Yamamoto, Toru Nakamura, Yuta Ushida, Vismaya Bachu, William R Burns, Yosuke Inoue, Yu Takahashi, Zohra Aslami, Richard D Schulick, Jin He, Wells Messersmith, Marc G Besselink, Richard A Burkhart, Johanna W Wilmink, Marco Del Chiaro, |
| 発行年月 | 2025/05 |
| 概要 | BACKGROUND:It remains unclear whether there is a difference in overall survival (OS) benefit between (m)FOLFIRINOX and gemcitabine-nab-paclitaxel as preoperative regimens for localised pancreatic adenocarcinoma. This study aimed to investigate the outcome of patients with resected localised pancreatic adenocarcinoma following (m)FOLFIRINOX versus gemcitabine-nab-paclitaxel.METHODS:International multicentre retrospective study (16 centres, 8 countries, 3 continents), including consecutive patients after pancreatic resection for localised pancreatic adenocarcinoma following 2-6 months preoperative (m)FOLFIRINOX or gemcitabine-nab-paclitaxel (2010-2018). Primary endpoint was OS from start of preoperative chemotherapy. Cox regression analysis was performed to investigate the association of the preoperative chemotherapy regimen with OS, adjusted for confounders at diagnosis.RESULTS:Overall, 935 patients were included after resection of localised pancreatic adenocarcinoma following preoperative (m)FOLFIRINOX (65%) or gemcitabine-nab-paclitaxel (35%). Preoperative chemotherapy regimen (m)FOLFIRINOX was not associated with OS (HR = 0.83 [95% CI 0.64-1.08]), compared to gemcitabine-nab-paclitaxel. Interaction analysis showed stronger effect of (m)FOLFIRINOX in patients with a lower (i.e., non-elevated/marginally elevated) serum CA19-9 at diagnosis (pinteraction = 0.032).CONCLUSION:This international study found no OS benefit of preoperative (m)FOLFIRINOX in patients with resected localised pancreatic adenocarcinoma compared to gemcitabine-nab-paclitaxel. |
| DOI | 10.1038/s41416-025-03025-1 |
| PMID | 40328917 |